AOD-9604 (2mg)

AOD-9604 (Anti-Obesity Drug 9604) is a synthetic peptide fragment comprising the C-terminal region of human growth hormone (hGH), specifically residues 176–191. It was originally developed in Australia by Metabolic Pharmaceuticals and has been the subject of clinical research into lipolysis and metabolic regulation, progressing further through clinical development than most peptides in its class.

What Is AOD-9604?

AOD-9604 was designed to isolate the fat-metabolising properties of human growth hormone without the insulin-desensitising effects associated with full hGH administration. The hGH fragment 176–191 was identified as the region responsible for the hormone’s lipolytic activity — and AOD-9604 is the stabilised, research-grade analogue of this fragment.

As an Australian-developed peptide, AOD-9604 holds a notable position in the peptide research landscape. It is one of the few research peptides to have progressed through Phase 1, Phase 2, and Phase 3 clinical trials, reaching TGA and FDA regulatory review for obesity treatment in the mid-2000s. While it did not achieve final approval as an anti-obesity therapeutic, it received Generally Recognised as Safe (GRAS) status in the United States — an unusual designation for a peptide compound.

AOD-9604 Research Background

Lipolysis research: Preclinical studies in obese rodent models demonstrated that AOD-9604 stimulated lipolysis (fat breakdown) and inhibited lipogenesis (fat formation) without affecting blood glucose levels or producing the growth-promoting effects associated with whole hGH. This selectivity was the basis for its advancement into clinical trials.

Clinical trial history: AOD-9604 completed Phase 3 trials (the METRO trials) in obese patients. While statistically significant weight loss was not demonstrated at the doses and study durations tested, the trials provided a substantial safety profile dataset. A 24-week study of 300+ participants established its tolerability.

GRAS status: The FDA’s GRAS determination for AOD-9604 makes it one of the more extensively characterised research peptides from a regulatory safety data perspective — a distinction shared by very few compounds in this class.

Cartilage and bone research: More recently, AOD-9604 has been investigated in preclinical models of osteoarthritis and cartilage repair, with researchers examining its potential to stimulate cartilage tissue regeneration independent of its metabolic effects.

Why AOD-9604 Interests Australian Researchers

As a domestically developed compound with a well-documented clinical trial history, AOD-9604 occupies a unique position in peptide research. The depth of its clinical data — including multiple Phase 3 trials and a GRAS determination — means its pharmacokinetic and safety profile is better characterised than most research peptides available today.

Reconstitution Guidelines (Research Use)

AOD-9604 is supplied as lyophilised powder. Reconstitute with bacteriostatic water.

Recommended concentration: 1mg/ml to 2mg/ml.

For precise volume calculations: Peptide Reconstitution Calculator

Storage

• Lyophilised powder: 2–8°C, protected from light
• Reconstituted: 2–8°C, use within 28 days
• Long-term: -20°C

VITALITY CARTEL AOD-9604

99%+ purity, third-party HPLC verified. CoA available on request. Domestic AU dispatch.